140 results on '"Rodríguez-Torres M"'
Search Results
2. Projection to latent structures regression and its application to Mach–Zehnder interferometer optical fiber sensors for acetone detection
3. Combined loss of CDH1 and downstream regulatory sequences drive early-onset diffuse gastric cancer and increase penetrance of hereditary diffuse gastric cancer.
4. Strong Association of Socioeconomic Status and Genetic Ancestry in Latinos: Implications for Admixture Studies of Type 2 Diabetes
5. UV photochemical synthesis of heparin-coated gold nanoparticles
6. Strong association of socioeconomic status with genetic ancestry in Latinos: implications for admixture studies of type 2 diabetes
7. Optimized threshold for serum HCV RNA to predict treatment outcomes in hepatitis C patients receiving peginterferon alfa-2a/ribavirin
8. Investigation of the “composition-pulling or lattice-latching” effect in LPE
9. Occult Hepatitis B Virus Infection in The Setting of Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV) Co-infection: Clinically Relevant or a Diagnostic Problem?
10. PS008 - High Efficacy of Sofosbuvir/Velpatasvir Plus GS-9857 for 12 Weeks in Treatment-Experienced Genotype 1-6 HCV-Infected Patients, Including Those Previously Treated with Direct-Acting Antivirals
11. SAT-173 - SOF/VEL for 12 Weeks Is Well Tolerated and Results in High SVR12 Rates in People Receiving Opioid Substitution Therapy
12. UV photochemical synthesis of heparin-coated gold nanoparticles
13. UVA mediated synthesis of gold nanoparticles in pharmaceutical-grade heparin sodium solutions
14. P0898 : TD-6450, A next generation once-daily NS5A inhibitor, has potent antiviral activity following a 3-day monotherapy study in genotype 1 HCV infection
15. P0901 : The pan-genotypic NS3/4A protease inhibitor GS-9857 demonstrates potent antiviral activity in patients infected with HCV genotype 1, 2, 3 or 4 in a 3-day monotherapy study
16. O165 SIMEPREVIR PLUS SOFOSBUVIR WITH/WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL-RESPONDER/TREATMENT-NAIVE PATIENTS (COSMOS STUDY): PRIMARY ENDPOINT (SVR12) RESULTS IN PATIENTS WITH METAVIR F3–4 (COHORT 2)
17. P1222 A PHASE II STUDY OF SAMATASVIR (IDX719) IN COMBINATION WITH SIMEPREVIR AND RIBAVIRIN IN TREATMENT-NAÏVE HCV-INFECTED SUBJECTS WITH GENOTYPES 1B AND 4 (HELIX-1 STUDY)
18. P1173 THE IMPACT OF HIV CO-INFECTION ON RATES AND SEVERITY OF ANEMIA OCCURRING DURING TREATMENT WITH SOFOSBUVIR-CONTAINING HCV REGIMENS: A POOLED ANALYSIS
19. P1126 IMPACT OF SAFETY-RELATED DOSE REDUCTIONS AND DISCONTINUATIONS (SR-RD) ON SUSTAINED VIROLOGICAL RESPONSE (SVR) IN TREATMENT-NAIVE CHRONIC HEPATITIS C PATIENTS RECEIVING PEGINTERFERON ALFA-2a/RIBAVIRIN: RESULTS FROM GUARD-C
20. O7 ONCE-DAILY SIMEPREVIR (TMC435) PLUS SOFOSBUVIR (GS-7977) WITH OR WITHOUT RIBAVIRIN IN HCV GENOTYPE 1 PRIOR NULL RESPONDERS WITH METAVIR F0–2: COSMOS STUDY SUBGROUP ANALYSIS
21. 1423 INTERIM ANALYSIS OF AN INTERFERON (IFN)- AND RIBAVIRIN (RBV)-FREE REGIMEN OF DACLATASVIR (DCV), ASUNAPREVIR (ASV), AND BMS-791325 IN TREATMENT-NAIVE, HEPATITIS C VIRUS GENOTYPE 1-INFECTED PATIENTS
22. 1417 SUSTAINED VIROLOGIC RESPONSE WITH DACLATASVIR PLUS SOFOSBUVIR ± RIBAVIRIN (RBV) IN CHRONIC HCV GENOTYPE (GT) 1-INFECTED PATIENTS WHO PREVIOUSLY FAILED TELAPREVIR (TVR) OR BOCEPREVIR (BOC)
23. 1411 SOFOSBUVIR + PEGINTERFERON + RIBAVIRIN FOR 12 WEEKS ACHIEVES 90% SVR12 IN GENOTYPE 1, 4, 5, OR 6 HCV INFECTED PATIENTS: THE NEUTRINO STUDY
24. 1206 PHARMACODYNAMICS OF ORAL TLR-7 AGONIST GS-9620 IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HEPATITIS C
25. 1196 ANALYSIS OF THE KINETICS OF VIRAL DECLINE DURING 14 DAYS OF ADMINISTRATION OF SOFOSBUVIR AND GS-0938
26. 845 ONCE DAILY SOFOSBUVIR PLUS RIBAVIRIN FOR 12 AND 24 WEEKS IN TREATMENT-NAÏVE PATIENTS WITH HCV INFECTION: THE QUANTUM STUDY
27. 106 SUSTAINED VIRAL RESPONSE AND SAFETY OF MK-7009 IN CIRRHOTIC TREATMENT-EXPERIENCED PATIENTS WITH GENOTYPE 1 HCV INFECTION WHO HAVE FAILED PREVIOUS PEGYLATED INTERFERON AND RIBAVIRIN TREATMENT
28. 5 PHASE 3 RANDOMIZED CONTROLLED TRIAL OF ALL-ORAL TREATMENT WITH SOFOSBUVIR + RIBAVIRIN FOR 12 WEEKS COMPARED TO 24 WEEKS OF PEG + RIBAVIRIN IN TREATMENT-NAÏVE GT2/3 HCV-INFECTED PATIENTS (FISSION)
29. Focus on drug interactions: the challenge of treating hepatitis C virus infection with direct-acting antiviral drugs in the HIV-positive patient.
30. 1421 HIGH SUSTAINED VIROLOGIC RESPONSE RATE IN TREATMENT-NAIVE HCV GENOTYPE 1A AND 1B PATIENTS TREATED FOR 12 WEEKS WITH AN INTERFERON-FREE ALL-ORAL QUAD REGIMEN: INTERIM RESULTS
31. 1422 POTENT VIRAL SUPPRESSION WITH ALL-ORAL COMBINATION OF DACLATASVIR (NS5A INHIBITOR) AND GS-7977 (NS5B INHIBITOR), +/− RIBAVIRIN, IN TREATMENT-NAIVE PATIENTS WITH CHRONIC HCV GT1, 2, OR 3
32. 1415 CONFIRMATION THAT QUADRUPLE THERAPY WITH DACLATASVIR (NS5A INHIBITOR), ASUNAPREVIR (NS3 INHIBITOR) AND PEGINTERFERON/RIBAVIRIN RESULTS IN HIGH RATE OF SVR4 IN HCV GENOTYPE 1 NULL RESPONDERS
33. 1179 IMPACT OF IL28B GENOTYPE ON VIROLOGIC RESPONSE IN PRIOR TREATMENT FAILURE PATIENTS WHO RECEIVED MK-7009 IN COMBINATION WITH PEGINTERFERON AND RIBAVIRIN
34. 1213 EFFICACY AND SAFETY OF MERICITABINE (MCB) IN COMBINATION WITH PEG-IFNa-2A/RBV IN G1/4 TREATMENT NAIVE HCV PATIENTS: FINAL ANALYSIS FROM THE PROPEL STUDY
35. 1189 GS-9669, A NOVEL NS5B NON-NUCLEOTIDE SITE II INHIBITOR, DEMONSTRATES POTENT ANTIVIRAL ACTIVITY, FAVORABLE SAFETY PROFILE AND POTENTIAL FOR ONCE-DAILY DOSING
36. 1188 GS-6620, A LIVER-TARGETED NUCLEOTIDE PRODRUG, EXHIBITS ANTIVIRAL ACTIVITY AND FAVORABLE SAFETY PROFILE OVER 5 DAYS IN TREATMENT NAIVE CHRONIC HCV GENOTYPE 1 SUBJECTS
37. 1153 THE EFFECT OF HEPATIC IMPAIRMENT ON THE SAFETY, PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-938 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS
38. 1134 PREMATURE TREATMENT DISCONTINUATION OF PEG-IFNa-2A/RBV DUE TO GOOD VIRAL RESPONSES AND INSUFFICIENT VIRAL RESPONSES AMONG HCV GENOTYPE 1, 2 AND 3 PATIENTS FROM PROPHESYS
39. 1130 THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND ANTIVIRAL ACTIVITY OF PSI-7977 IN HEPATITIS C INFECTED SUBJECTS TREATED FOR SEVEN DAYS
40. 73 WORLDWIDE EXPERIENCE TREATING CHRONIC HEPATITIS C (CHC) WITH PEGINTERFERON ALFA/RIBAVIRIN: FINAL RESULTS FROM 7163 NAIVE, MONO-INFECTED PATIENTS ENROLLED IN THE LARGE MULTINATIONAL PROPHESYS COHORT STUDY
41. 60 RESULTS OF ENABLE 2, A PHASE 3, MULTICENTER STUDY OF ELTROMBOPAG AND PEGINTERFERON ALFA-2B TREATMENT IN PATIENTS WITH HEPATITIS C AND THROMBOCYTOPENIA
42. 58 FINAL RESULTS – RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SAFETY, ANTI-VIRAL PROOF-OF-CONCEPT STUDY OF MIRAVIRSEN, AN OLIGONUCLEOTIDE TARGETING MIR-122, IN TREATMENT-NAIVE PATIENTS WITH GENOTYPE 1 CHRONIC HCV INFECTION
43. 10 PEGINTERFERON LAMBDA-1A (LAMBDA) COMPARED TO PEGINTERFERON ALFA-2A (ALFA) IN TREATMENT-NAIVE PATIENTS WITH HCV GENOTYPES (G) 2 OR 3: FIRST SVR24 RESULTS FROM EMERGE PHASE IIB
44. 7 PSI-7977 PROTON AND ELECTRON: 100% CONCORDANCE OF SVR4 WITH SVR24 IN HCV GT1, GT2, & GT3
45. 1360 PEGYLATED INTERFERON-LAMBDA (PEGIFN-λ) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFNα-2A IN HCV PATIENTS (Gl/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12
46. 1372 ONCE DAILY PSI-7977 PLUS PEG-IFN/RBV IN HCV GT1: 98% RAPID VIROLOGIC RESPONSE, COMPLETE EARLY VIROLOGIC RESPONSE: THE PROTON STUDY
47. 1370 ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCVRNA
48. 1235 PSI-352938, A NOVEL PURINE NUCLEOTIDE ANALOG, EXHIBITS POTENT ANTIVIRAL ACTIVITY AND NO EVIDENCE OF RESISTANCE IN PATIENTS WITH HCV GENOTYPE 1 OVER 7 DAYS
49. 468 UNIQUE PATTERN OF VIROLOGIC RESPONSE IN PATIENTS WITH GENOTYPE-1 HCV: A PHASE II STUDY OF CTS-1027 IN COMBINATION WITH PEGINTERFERON/RIBAVIRIN (SOC) IN NULL RESPONDERS
50. 431 SVR RATES ARE HIGHER AMONG HCV G1 PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN (LDL) LEVELS WHEN TREATED WITH INTENSIFIED DOSES OF PEGINTERFERON ALFA-2A (PEGASYS®) PLUS RIBAVIRIN
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.